Larimar Therapeutics, Inc.
LRMRNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$172.5M | −$90.9M | −$41.8M | −$36.5M | −$50.5M | −$42.8M |
| Net income | −$165.7M | −$80.6M | −$36.9M | −$35.4M | −$50.6M | −$42.5M |
| Total assets | $145.8M | $200.2M | $95.9M | $126.4M | $78.7M | $104.7M |
| Total liabilities | $67.8M | $28.4M | $14.2M | $15.5M | $14.3M | $15.0M |
| Equity | $78.1M | $171.8M | $81.7M | $110.9M | $64.4M | $89.7M |
| EPS (diluted) | — | $-1.32 | $-0.84 | $-1.37 | $-2.95 | $-3.57 |
| Shares out. | 64.0M | 63.8M | 43.3M | 17.7M | 15.4M | 37.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −212.2%
- Return on assets
- −113.6%
- Return on capital (ROCE)
- −212.8%
- Liabilities / assets
- 46.5%
- Debt / equity
- 0.87×
- Book value / share
- $1.22
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -12.98distress
- Accruals / assets
- −36.0%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Blue Owl Capital Holdings LpPassive (13G)May 14, 2026
- Millennium Management LlcPassive (13G)Apr 30, 2026
- Flynn James EActivist (13D)Mar 2, 2026
- Ra Capital Management, L.P.Passive (13G)Feb 17, 2026
- Opaleye Management Inc.Passive (13G)Aug 29, 2025
- Janus Henderson Group PlcPassive (13G)Aug 14, 2025
- Goldman Sachs Group IncPassive (13G)May 13, 2025
- Blackrock, Inc.Passive (13G)Apr 22, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Flynn James EDirector | Feb 27, 2026 | Buy | 1.1M | $5.00 |
| Hamilton Thomas EdwardDirector | Feb 27, 2026 | Buy | 100,000 | $5.00 |
| Thomas Frank EDirector | Feb 27, 2026 | Buy | 5,000 | $5.00 |
| Sherman Jeffrey WDirector | Feb 27, 2026 | Buy | 5,000 | $5.00 |
| Shankar GopiOfficer — Chief Development Officer | Jan 26, 2026 | Grant | 25,637 | $0.00 |
| Clayton RussellOfficer — Chief Medical Officer | Jan 26, 2026 | Grant | 25,637 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 8.7M | 4.3 | +5.2% |
| Apr 30, 2026 | 8.3M | 7.0 | +13.3% |
| Apr 15, 2026 | 7.3M | 5.0 | -4.0% |
| Mar 31, 2026 | 7.6M | 3.9 | +5.3% |
| Mar 13, 2026 | 7.3M | 2.7 | -5.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 19, 2026
- Results of operations · Other material eventMay 14, 2026
- Results of operationsMar 19, 2026
- Other material eventMar 9, 2026
- Entered a material agreementFeb 27, 2026
- Other material eventFeb 24, 2026
- Unregistered equity sale · Amended charter or bylawsJan 22, 2026
- Results of operations · Other material eventJan 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.